Bleomycin: A novel osteogenesis inhibitor of dental follicle cells via a TGF‐β1/SMAD7/RUNX2 pathway

Zhi‐Zheng Li,Hai‐Tao Wang,Grace Y. Lee,Ying Yang,Yan‐Ping Zou,Bing Wang,Chu‐Jie Gong,Yu Cai,Jian‐Gang Ren,Ji‐Hong Zhao
DOI: https://doi.org/10.1111/bph.15281
IF: 7.3
2020-12-13
British Journal of Pharmacology
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Purpose</h3><p>Tooth eruption is a complicated process regulated by dental follicle (DF). Our recent study discovered that tooth eruption was inhibited upon injection of bleomycin (BLM) into DF. However, the mechanisms were unknown.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental Approach</h3><p>Human dental follicle cells (hDFCs) were treated by BLM or exogenous TGF‐β1, or transfected by plasmids loading SMAD7 or shRNA targeting SMAD7, followed by osteogenesis induction assay and signaling analysis. Human fresh DF tissues and Wistar rats were used to further confirm BLM function.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key Results</h3><p>Our data showed that BLM decreased RUNX2 and osteogenic genes expression in hDFCs, causing reduced osteogenic capacity. TGF‐β1 expression was upregulated in BLM treated hDFCs. The effects of exogenous TGF‐β1 were similar to BLM in hDFCs. Additionally, compared to SMAD2/3, SMAD7 expression increased more dramatically in BLM or TGF‐β1 treated hDFCs. Overexpression of SMAD7 likewise significantly decreased RUNX2 expression and osteogenic capacity of hDFCs. Knockdown of SMAD7 dramatically attenuated the inhibitory effects of BLM and TGF‐β1 on osteogenic capacity and RUNX2 expression of hDFCs. Most importantly, changes in TGF‐β1, SMAD7 and RUNX2 expressions were similar in the DF of rats and humans treated with BLM.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion and Implications</h3><p>SMAD7 was a negative regulator of osteogenic differentiation in DFCs through suppressing RUNX2 expression. BLM or TGF‐β1 inhibited osteogenic differentiation of DFCs via TGF‐β1/SMAD7/RUNX2 pathway. Our findings might be beneficial for enhancing the osteogenic activity of DFCs or inhibiting the eruption of undesirable teeth.</p></section>
pharmacology & pharmacy
What problem does this paper attempt to address?